Overview

A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)

Status:
Active, not recruiting

Trial end date:
2021-11-12

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety, tolerability and efficacy of LY3002813 in early symptomatic Alzheimer's disease.

Phase:

Phase 2

Details

Lead Sponsor:

Eli Lilly and Company